Jonathan Kay to United States Food and Drug Administration
This is a "connection" page, showing publications Jonathan Kay has written about United States Food and Drug Administration.
Connection Strength
1.087
-
Kay J, Nikolov NP, Weisman MH. American College of Rheumatology and Food and Drug Administration Summit: Summary of the Meeting, May 17-18, 2022. Arthritis Rheumatol. 2024 Sep; 76(9):1323-1333.
Score: 0.879
-
Alvarez DF, Wolbink G, Cronenberger C, Orazem J, Kay J. Interchangeability of Biosimilars: What Level of Clinical Evidence is Needed to Support the Interchangeability Designation in the United States? BioDrugs. 2020 Dec; 34(6):723-732.
Score: 0.173
-
Bridges SL, White DW, Worthing AB, Gravallese EM, O'Dell JR, Nola K, Kay J, Cohen SB. The Science Behind Biosimilars: Entering a New Era of Biologic Therapy. Arthritis Rheumatol. 2018 03; 70(3):334-344.
Score: 0.036